Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
To learn if the drug combination of BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab can help to control advanced or metastatic MSS-CRC.
Microsatellite-stable Colorectal Cancer|Standard of Care|Nivolumab|Bevacizumab
DRUG: Nivolumab|DRUG: Bevacizumab|DRUG: BMS-986340|DRUG: Trifluridine + Tipiracil
Safety and adverse events (AEs), Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0, Through study completion; an average of 1 year
Primary Objectives

* To determine the safety of the combination of BMS-986340, nivolumab, trifluridine/tipiracil and bevacizumab.
* To determine the objective response rate (ORR) of the BMS-986340, nivolumab, trifluridine/tipiracil and bevacizumab

Secondary Objectives

â€¢ To determine the progression-free survival (PFS), overall survival (OS) and duration of response (DOR) in participants with advanced or metastatic MSS-CRC.